1-oxyl-2-(3,4-dimethoxyphenyl)-3-oxo-4,4,5,5-tetramethyl-2-imidazoline | 898562-21-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-oxyl-2-(3,4-dimethoxyphenyl)-3-oxo-4,4,5,5-tetramethyl-2-imidazoline
• 英文别名: 2-(3',4'-dimethoxyphenyl)-4,4,5,5-tetramethylimidazolidine-3-oxide-1-oxyl；2-(3',4'-dimethoxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
• CAS: 898562-21-5
• 化学式: C₁₅H₂₁N₂O₄
• 分子量: 293.343
• InChiKey: QSKZTCJEIGLVFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  51.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-oxyl-2-(3,4-dimethoxyphenyl)-3-oxo-4,4,5,5-tetramethyl-2-imidazoline 在 盐酸 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以50%的产率得到1-oxyl-2-(3,4-dimethoxyphenyl)-4,4,5,5-tetramethyl-2-imidazoline
  参考文献：
  名称：

  Novel 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines: Synthesis, selectively analgesic action, and QSAR analysis

  摘要：

  Based on the knowledge that imidazoline can result in analgesic action due to its selective binding with the prostacyclin receptor, 20 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines (3a-t) were prepared in moderate yields. At 0.13 mmol/kg dose, their in vivo analgesic activities were evaluated after the mice were administered at 30, 60, 90, and 150 min. Compared with the pain threshold (12.27 +/- 9.56-17.71 +/- 7.00%) of normal saline (NS) receiving mice, the pain threshold (23.42 +/- 8.14% to 102.58 +/- 10.66%) of 3a-t receiving mice increases significantly. Considering a prostacyclin receptor targeting analgesic agent usually had bleeding action and to appraise the bleeding risk, the in vivo tail bleeding time of 1.30 mmol/kg 3a-t receiving mice was found to be ranged from 116.3 +/- 8.2 s to 120.3 +/- 9.2 s, which was substantially equal to that (117.8 +/- 8.4 s to 119.0 +/- 8.6 s) of NS receiving mice. Based on the possibility of imidazoline acting as vasodilator, the in vitro vasorelaxations of 3a-t were tested using the rat aortic strip model. When the aortic strip contracted by noradrenaline (NE, final concentration 10(-7) mol/l) was treated with 3a-t (final concentration 5 x 10(-4) mol/l), only lower percentage inhibitions (6.55 +/- 5.70-37.40 +/- 4.07%) were recorded, implying that the vasorelaxation of 3a-t was neglectable. By selecting appropriate molecular descriptors generated from e-dragon server, the QSAR model of the analgesic activities of 3a-t was constructed using the multiple linear regression method. The established QSAR model showed reasonable accuracy and thus it is promising to be used for screening new 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazoline derivatives as analgesic agents. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.02.023
• 作为产物：
  描述：

  2,3-二甲基-2,3-二硝基丁烷 在 氯化铵 、 lead dioxide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 35.33h， 生成 1-oxyl-2-(3,4-dimethoxyphenyl)-3-oxo-4,4,5,5-tetramethyl-2-imidazoline
  参考文献：
  名称：

  作为自由基清除剂的新型2-取代硝酰基硝基氧化合物：合成，生物学评估和结构-活性关系。

  摘要：

  为了开发具有增强的自由基清除剂性能的更有效的小分子，我们设计并合成了一系列硝酰基硝基氧衍生物4a-h。基于Ach诱导的血管舒张测定法发现了前导化合物4f。基于该支架的进一步化学修饰提供了一系列新的2-取代的苯基亚硝酰基硝基氧化物衍生物6a-s。基于PC12细胞存活测定法，新合成的化合物6a-s具有改善的自由基清除剂的活性。就NO，H（2）O（2）和OH的清除能力而言，化合物6g，n，o和s是一些最有效的化合物。2-取代的苯基亚硝基硝基氮氧化物具有较高的自由基清除活性，带有给电子基团（EDG）。相比之下，吸电子基团（EWG）引入芳环导致其自由基清除活性急剧下降。这些结果表明，芳香环的给电子基团（EDG）可能是影响这些化合物清除自由基行为的重要因素，清除自由基的能力很大程度上取决于苯环的位置和电子性质。取代基。新型的2-取代的硝酰基氮氧化物的增强的自由基清除能力可能是对抗ROS（活性氧）/ R

  DOI：

  10.1016/j.bmc.2006.04.016

文献信息

• Novel 2-substituted nitronyl nitroxides as free radical scavengers: Synthesis, biological evaluation and structure–activity relationship
  作者：Yihui Wu、Lanrong Bi、Wei Bi、Zeng Li、Ming Zhao、Chao Wang、Jingfang Ju、Shiqi Peng

  DOI：10.1016/j.bmc.2006.04.016

  日期：2006.8

  nitroxide derivatives 4a-h. A lead compound 4f was discovered based on Ach-induced vascorelaxation assay. Further chemical modification based on this scaffold provided a new series of 2-substituted phenylnitronyl nitroxide derivatives 6a-s. The newly synthesized compounds 6a-s possess improved radical scavenger's activity based on PC12 cell survival assay. Compounds 6g,n,o, and s are some of the most

  为了开发具有增强的自由基清除剂性能的更有效的小分子，我们设计并合成了一系列硝酰基硝基氧衍生物4a-h。基于Ach诱导的血管舒张测定法发现了前导化合物4f。基于该支架的进一步化学修饰提供了一系列新的2-取代的苯基亚硝酰基硝基氧化物衍生物6a-s。基于PC12细胞存活测定法，新合成的化合物6a-s具有改善的自由基清除剂的活性。就NO，H（2）O（2）和OH的清除能力而言，化合物6g，n，o和s是一些最有效的化合物。2-取代的苯基亚硝基硝基氮氧化物具有较高的自由基清除活性，带有给电子基团（EDG）。相比之下，吸电子基团（EWG）引入芳环导致其自由基清除活性急剧下降。这些结果表明，芳香环的给电子基团（EDG）可能是影响这些化合物清除自由基行为的重要因素，清除自由基的能力很大程度上取决于苯环的位置和电子性质。取代基。新型的2-取代的硝酰基氮氧化物的增强的自由基清除能力可能是对抗ROS（活性氧）/ R
• Synthesis, Crystal Structure, and Magnetic Property of New Trispin Ln(III)-Nitronyl Nitroxide Complexes
  作者：Zhe Fan、Yi-Fang Hou、Shu-Ping Wang、Shu-Tao Yang、Jian-Jun Zhang、Shi-Kao Shi、Li-Na Geng

  DOI：10.1002/hlca.201600152

  日期：2016.9

  Four Ln(III) complexes based on a new nitronyl nitroxide radical have been synthesized and structurally characterized: Ln(hfac)3[NITPh(MeO)2]2} (Ln = Eu(1), Gd(2), Tb(3), Dy(4); NITPh(MeO)2 = 2‐(3′,4′‐dimethoxyphenyl)‐4,4,5,5‐tetramethylimidazoline‐1‐oxyl‐3‐oxide; hfac = hexafluoroacetylacetonate). The single‐crystal X‐ray diffraction analysis shows that these complexes have similar mononuclear trispin

  合成了四种基于新的硝酰基硝基氧自由基的Ln（III）配合物，并对其结构进行了表征：Ln（hfac）3 [NITPh（MeO）2 ] 2 }（Ln = Eu（1），Gd（2），Tb（3），Dy（4）; NITPh（MeO）2 = 2-（3'，4'-二甲氧基苯基）-4,4,5,5-四甲基咪唑啉-1-氧-3-氧化物; hfac =六氟乙酰丙酮）。X射线单晶衍射分析表明，这些配合物具有相似的单核三旋结构，其中中心Ln（III）离子与两个氮氧根基团的两个O原子和三个hfac阴离子的六个O原子配位。可变温度磁化率研究表明，Gd（III）与自由基之间存在铁磁相互作用，两个自由基之间存在反铁磁相互作用（J G d‐Rad  = 3.40 cm -1，J R ad‐Rad  = −9.99 cm -1）在复数2中。同时，反铁磁相互作用被铕（III）（或镝（III））和自由基之间估计在复合物1和4，和Tb（
• TPAP/NMO System as a Novel Method for the Synthesis of Nitronyl Nitroxide Radicals
  作者：Lapo Gorini、Andrea Caneschi、Stefano Menichetti

  DOI：10.1055/s-2006-939045

  日期：——

  An easy oxidation of dihydroxyimidazolidine derivatives to nitronyl nitroxide radicals (NNRs) can be achieved using the tetra-N-propylamonium perruthenate/N-methylmorpholine N-oxide (TPAP/NMO) system. The procedure offers several advantages in terms of simplicity, yield, cost and ‘green’ chemistry.

  利用四-N-丙基铵过钌酸盐/N-甲基吗啉 N-氧化物（TPAP/NMO）体系，可以轻松地将二羟基咪唑烷衍生物氧化成硝基亚硝基自由基（NNRs）。该方法在操作简单、产量高、成本低和 "绿色 "化学方面具有诸多优势。
• Novel 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines: Synthesis, selectively analgesic action, and QSAR analysis
  作者：Ming Zhao、Zheng Li、Li Peng、Yu-Rong Tang、Chao Wang、Ziding Zhang、Shiqi Peng

  DOI：10.1016/j.bmc.2007.02.023

  日期：2007.4

  Based on the knowledge that imidazoline can result in analgesic action due to its selective binding with the prostacyclin receptor, 20 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines (3a-t) were prepared in moderate yields. At 0.13 mmol/kg dose, their in vivo analgesic activities were evaluated after the mice were administered at 30, 60, 90, and 150 min. Compared with the pain threshold (12.27 +/- 9.56-17.71 +/- 7.00%) of normal saline (NS) receiving mice, the pain threshold (23.42 +/- 8.14% to 102.58 +/- 10.66%) of 3a-t receiving mice increases significantly. Considering a prostacyclin receptor targeting analgesic agent usually had bleeding action and to appraise the bleeding risk, the in vivo tail bleeding time of 1.30 mmol/kg 3a-t receiving mice was found to be ranged from 116.3 +/- 8.2 s to 120.3 +/- 9.2 s, which was substantially equal to that (117.8 +/- 8.4 s to 119.0 +/- 8.6 s) of NS receiving mice. Based on the possibility of imidazoline acting as vasodilator, the in vitro vasorelaxations of 3a-t were tested using the rat aortic strip model. When the aortic strip contracted by noradrenaline (NE, final concentration 10(-7) mol/l) was treated with 3a-t (final concentration 5 x 10(-4) mol/l), only lower percentage inhibitions (6.55 +/- 5.70-37.40 +/- 4.07%) were recorded, implying that the vasorelaxation of 3a-t was neglectable. By selecting appropriate molecular descriptors generated from e-dragon server, the QSAR model of the analgesic activities of 3a-t was constructed using the multiple linear regression method. The established QSAR model showed reasonable accuracy and thus it is promising to be used for screening new 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazoline derivatives as analgesic agents. (c) 2007 Elsevier Ltd. All rights reserved.